Exo Therapeutics utilizes its ExoSight™ platform to identify and develop small molecule inhibitors targeting exosites on enzymes involved in oncology and inflammation. This approach aims to enhance the modulation of enzyme activity, addressing the challenge of drugging previously inaccessible targets.
Funding
$102.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many enzymes implicated in oncology and inflammation are difficult to target with traditional active-site inhibitors, limiting therapeutic options. These enzymes often possess exosites, allosteric binding pockets distinct from the active site, which can modulate enzyme activity but are challenging to identify and drug.
Solution
Exo Therapeutics leverages its ExoSight™ platform to discover and develop small molecule inhibitors that target exosites on enzymes relevant to oncology and inflammation. By focusing on these exosites, Exo Therapeutics aims to achieve more precise and potent modulation of enzyme activity compared to conventional active-site targeting. This approach expands the druggable target space, potentially unlocking new therapeutic interventions for diseases where traditional methods have proven insufficient. The ExoSight™ platform provides a comprehensive approach to identify and characterize exosites, enabling the design of selective inhibitors.
Target Audience
The primary target audience includes patients with cancer and inflammatory diseases, as well as pharmaceutical companies seeking novel drug targets and therapeutic strategies.
Features
- ExoSight™ platform for exosite identification and characterization
- Development of small molecule inhibitors targeting enzyme exosites
- Focus on oncology and inflammation pathways
- Precise and potent modulation of enzyme activity
- Potential to drug previously intractable targets